Medication use in pregnancy and the pregnancy and lactation labeling rule

2016 ◽  
Vol 100 (1) ◽  
pp. 23-25 ◽  
Author(s):  
L Sahin ◽  
SC Nallani ◽  
MS Tassinari

Author(s):  
Claire M. McCarthy ◽  
Fergal O’Shaughnessy ◽  
Nicola Maher ◽  
Brian J. Cleary ◽  
Jennifer C. Donnelly


2013 ◽  
Vol 18 (3) ◽  
pp. 247-258 ◽  
Author(s):  
Betsy Walters Burkey ◽  
Amy P. Holmes

As a pharmacist, being asked to give advice about medication use during pregnancy or lactation can be daunting. This article reviews the principles of drug transfer across the placenta, into breast milk, and reviews the rating scales and different resources available. The Food and Drug Administration classification scale is reviewed and the upcoming changes are explained, along with recent labeling changes for specific medications or drug classes when appropriate. This article provides the pharmacist with a practical set of tools to review the information available and assess the risks of treating or withholding a medication for mother and infant.







2018 ◽  
Vol 52 (8) ◽  
pp. 810-818 ◽  
Author(s):  
Brooke L. Griffin ◽  
Rebecca H. Stone ◽  
Shareen Y. El-Ibiary ◽  
Sarah Westberg ◽  
Kayce Shealy ◽  
...  

Objective: To provide guidance for clinicians on risk assessment of medication use during pregnancy and lactation. Data Sources: Authors completed PubMed searches to identify articles focused on the use of medications in pregnancy, including fetal development, drug transfer across the placenta, trimester exposure, chronic conditions in pregnancy, medications in lactation, and lactation and chronic disease. Study Selection and Data Extraction: Articles were reviewed to provide overall guidance to medication selection during pregnancy. The following information was reviewed: medication use in pregnancy, including fetal development, drug transfer across the placenta, trimester exposure, chronic conditions in pregnancy, medications in lactation, and lactation and chronic disease. Data Synthesis: This article will provide an overview of medication safety considerations during pregnancy and lactation. Information was interpreted to help clinicians predict the potential risk and benefit in each patient to make an evidence-based decision. The article concludes with guidance on risk assessment and how pharmacists may support fellow health care providers and their patients when considering medication use. Conclusions: Information about the effects of medication use during reproductive periods is limited. With the removal of the Food and Drug Administration pregnancy categories, clinicians will be relying on pharmacists to aid in the appropriate selection of therapies for patients. It is critical that pharmacists keep abreast of resources available and be able to assess data to help prescribers and their patients.



1962 ◽  
Vol 40 (3) ◽  
pp. 430-440 ◽  
Author(s):  
K. E. Arosenius ◽  
H. Derblom ◽  
G. Nylander

ABSTRACT The offspring of bitches treated with thiouracil during pregnancy and lactation were studied with regard to certain aspects of iodine metabolism and also to the morphological effect on the thyroid gland, as compared with controls of the same age and weight. At the age of six months, when the dogs were virtually fully grown, the thyroid gland still exhibited the effects of the thiouracil treatment of the mothers as manifested by an increased uptake of 131I, enlargement, and histological changes of a hyperplastic type. The significance of these deviations from normal iodine metabolism and morphology is discussed with particular reference to the dangers of thiouracil medication during pregnancy.



Author(s):  
Ashley D. Davidson ◽  
Amritha Bhat ◽  
Frances Chu ◽  
Jessie N. Rice ◽  
N. Aba Nduom ◽  
...  




1976 ◽  
Vol 2 (4) ◽  
pp. 138-141 ◽  
Author(s):  
Jill M. Forrest


Sign in / Sign up

Export Citation Format

Share Document